Tumori Journal Abstract Book - October 2020 - 123

E - Breast Cancer
carriers (RR, 0.552; 95%CI, 0.448-0.682; RR, 0.114;
95%CI, 0.041-0.317, respectively) (Xiao Li, 2016). The
risk of contralateral breast cancer in women with a BRCA
mutation is approximately 40% at 10 years (Metcalfe K,
2014). Contralateral prophylactic mastectomy significantly decreased breast cancer incidence in BRCA1/2
mutation carriers (RR, 0.072; 95%CI, 0.035-0.148). The
radical surgical option which should be reserved for
patients with BRCA1/2 mutation and breast cancer diagnosis, is still debated. However, several aspects should be
considered before the radical surgical decision-making:
the risk of ipsilateral breast recurrence, the risk of contralateral breast cancer, the potential survival benefit, the
quality of life, woman's age, morbidity, type of mutation,
individual preferences and expectations and psychological-relational profiles. A multidisciplinary consultancy is
advisable. In the last few years the Genetic Counseling
Oncology (CGO), the Mammography Screening and the
Breast Unit of Mantova, have been sharing a PDTA to propose a tailored management for patients at increased risk
of breast-cancer.
Patients and results: Since 2016 in CGO-screening, 760
families have been selected for their risk of hereditary breast
and ovarian cancer. We identified 66 mutations (38 pathogenic mutations and 28 VUS, variants of uncertain significance) in 275 index cases. 56 patients, 20% of these index
cases, were discussed in the Breast Unit after radiological
and histological diagnosis of invasive breast cancer or DCIS.
To these patients, genetic counseling was recommended. 6 of
these women (10%) were BRCA-mutation carriers and they
accepted prophylactic mastectomy. Moreover 12 women, in
CGO-screening, BRCA-mutation carriers, after early diagnosis of breast cancer (60% pTis, 40% pT1), decided to get a
bilateral prophylactic mastectomy, which was proposed after
multidisciplinary discussion of each individual case. 12 of 18
patients accepted prophylactic bilateral oophorectomy and a
woman received a diagnosis of stage I ovarian cancer
throughout the procedure.
Conclusions: From our experience mutation carriers with
unilateral breast cancer need to be discussed by a multidisciplinary team and the counseling should be managed on a
case-by-case basis.

123
Background: LOX-1 is a membrane receptor encoded by
the OLR-1 gene, responsible for the recognition, binding and
internalization of oxidized low-density lipoproteins. Studies
in our laboratory showed that LOX-1 is overexpressed in different cancer types, including breast cancer (BC). Moreover,
LOX-1 expression in BC is closely related to the disease
molecular phenotype. LOX-1 may confer proliferative
advantage once overexpressed through expression vectors in
vitro, both in neoplastic cells and in stabilized normal cell
lines, modulating proteins involved in cell cycle regulation
and apoptosis. These data suggest that LOX-1 may represent
a new "metabolic" oncogene. The present work was aimed at
retrospectively evaluating in a series of BC patients the prognostic value of LOX-1, by correlating LOX-1 expression
with loco-regional and distant disease recurrence.
Patients and methods: Formalin-fixed, paraffin-embedded
specimens of 47 BC patients (pts) were assessed for LOX1by immunohistochemistry and pts' data on clinical-pathological prognostic markers were charted. Twenty-three of
those pts were assessable for either loco-regional or distant
relapsing disease along their 5 years follow-up and for the
potential prognostic value of LOX-1 expression.
Results: In 32 specimens of 47 (~70%) BC pts, a strong
upregulationof LOX-1 (tumors versus controls: p<0.01)
was observed, positively correlating to tumor stage (T) and
histological grade (G). A strong LOX-1 overexpression was
observed in invasive BC as compared to normal tissues of
the same individuals, aside the neoplasia (p<0.01). Eight
out of the 23 pts evaluated for disease recurrence showed a
relapsing disease. LOX-1 high expression was found in
75% of pts who showed relapsing disease, while LOX-1
low expression was found in 83% of cases with no evidence
of disease along their 5 years follow-up. When the prognostic value of LOX-1 expression was retrospectively evaluated in that cohort of pts, in comparison with T, nodal status
and G, LOX-1 expression and T size, N status, and G, were
all recognized as independent prognostic markers (further
correlations with the level of ER, PR, HER2 and Ki67 of BC
specimens will be shown during the meeting).
Conclusions: These preliminary data suggest that LOX-1
is a promising independent prognostic marker in BC pts.
However, larger correlative trials are needed to confirm
LOX-1 as a new prognostic marker and to define its potential role in the management of BC pts.

E45
LOX-1: a new potential prognostic
marker for breast cancer patients
Pucci S.1, Torino F.2, Polidoro C.3, Greggi C.3, Iossa F.3, Giannetti E.2,
Costantini M.4, Novelli G.3
1
Dipartimento di Biomedicina and Prevenzione, Università di Roma "Tor
Vergata", Roma; 2Oncologia Medica, Dipartimento Medicina dei Sistemi,
Università Roma Tor Vergata, Roma; 3Dipartimento di Biomedicina e
Prevenzione, Università di Roma Tor Vergata, Roma; 4IRCCS Isituto
Nazionale Tumori "Regina Elena", Roma, Roma

E46
Sexuality in cancer patients:
a study on female sexual
dysfunctions in women with
breast cancer
Aiello M.1, Moschetto M.2
1

A.O.U. Policlinico Vittorio Emanuele - U.O Oncologia Medica, Catania; 2AOU
Policlinico Vittorio Emanuele - U.O. Oncologia Medica, Catania

Tumori Journal Abstract Book - October 2020

Table of Contents for the Digital Edition of Tumori Journal Abstract Book - October 2020